Wise Young
09-29-2001, 11:24 PM
Beneficial autoimmunity in traumatic brain injury [Journal Club]
David Gurwitz
Trends in Molecular Medicine, 2001, 7:8:336
Abstract
There is no abstract for this article. The text below is the first paragraph of text within the article.
Traumatic brain injury or stroke-mediated primary central nervous system (CNS) damage is followed over the following few days by a self-propagating, slower, secondary damage, in which additional neurons die and the affected brain area is considerably enlarged. Neuroscientists have therefore striven to find effective strategies for minimizing the secondary damage, for which a relatively longer therapeutic time window might be available. Several lines of evidence suggest that immune activation, in particular elevated local levels of cytokines, adhesion molecules, prostanoids and inducible nitric oxide synthase, participate in the secondary damage. Hence, recent drug trials have targeted the immune system, seeking to reduce secondary traumatic brain damage by restraining the immune system. So far, results from such trials are not encouraging.
David Gurwitz
Trends in Molecular Medicine, 2001, 7:8:336
Abstract
There is no abstract for this article. The text below is the first paragraph of text within the article.
Traumatic brain injury or stroke-mediated primary central nervous system (CNS) damage is followed over the following few days by a self-propagating, slower, secondary damage, in which additional neurons die and the affected brain area is considerably enlarged. Neuroscientists have therefore striven to find effective strategies for minimizing the secondary damage, for which a relatively longer therapeutic time window might be available. Several lines of evidence suggest that immune activation, in particular elevated local levels of cytokines, adhesion molecules, prostanoids and inducible nitric oxide synthase, participate in the secondary damage. Hence, recent drug trials have targeted the immune system, seeking to reduce secondary traumatic brain damage by restraining the immune system. So far, results from such trials are not encouraging.